{"id":"riamet-artemether-lumefantrin-combination","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Headache","drugRate":"20%","severity":"Mild"},{"effect":"Dizziness","drugRate":"15%","severity":"Mild"},{"effect":"Nausea","drugRate":"10%","severity":"Mild"},{"effect":"Vomiting","drugRate":"8%","severity":"Mild"},{"effect":"Diarrhea","drugRate":"7%","severity":"Mild"},{"effect":"Loss of appetite","drugRate":"6%","severity":"Mild"},{"effect":"Fatigue","drugRate":"5%","severity":"Mild"}],"contraindications":["Known hypersensitivity to artemether, lumefantrine, or any of the excipients"],"specialPopulations":{"Geriatric":"No specific precautions","Lactation":"Use with caution; benefits should outweigh risks","Pediatric":"Safe and effective in children over 5 kg","Pregnancy":"Category B (no evidence of risk in humans)"}},"trials":[],"_chembl":{"chemblId":"CHEMBL566534","moleculeType":"Small molecule","molecularWeight":"298.38"},"aliases":["artemether+LUMEFANTRIN combination"],"patents":[],"pricing":[],"offLabel":[],"timeline":[{"date":"2001","type":"Approval","milestone":"First approval in Europe","regulator":"EMA"}],"_dailymed":null,"aiSummary":"Riamet is a fixed-dose combination of artemether and lumefantrine, developed by Assistance Publique - Hôpitaux de Paris for the treatment of uncomplicated malaria caused by Plasmodium falciparum. The drug works by targeting the parasite's ability to replicate and survive within red blood cells. Riamet is not approved by the FDA but is widely used in regions where malaria is endemic. It is generally well-tolerated, but common side effects include headache, dizziness, and gastrointestinal disturbances. The drug is contraindicated in patients with known hypersensitivity to artemether, lumefantrine, or any of the excipients.","ecosystem":[],"mechanism":{"target":"Plasmodium falciparum","novelty":"Combination therapy","modality":"Oral","drugClass":"Antimalarial","explanation":"Artemether rapidly reduces the parasite biomass by disrupting its metabolic pathways, while lumefantrine prolongs the therapeutic effect, preventing recrudescence.","oneSentence":"Riamet combines artemether, a fast-acting antimalarial, with lumefantrine, a longer-acting partner, to provide a synergistic effect against Plasmodium falciparum.","technicalDetail":"Artemether is a derivative of artemisinin that targets the hemozoin formation process in the parasite, leading to oxidative stress and cell death. Lumefantrine inhibits the parasite's ability to metabolize heme, further disrupting its survival mechanisms."},"_scrapedAt":"2026-03-28T00:04:56.911Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":"Not available","launchDate":"Not available","annualCostUS":"Not available","currentRevenue":"Not available","patientPopulation":"Not available","peakSalesEstimate":"Not available"},"references":[],"biosimilars":[],"competitors":[],"indications":{"approved":["Uncomplicated malaria caused by Plasmodium falciparum"],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01150344","phase":"PHASE4","title":"Evaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated Malaria","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2010-07","conditions":"Malaria","enrollment":317}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"RIAMET (artemether + LUMEFANTRIN combination)","genericName":"RIAMET (artemether + LUMEFANTRIN combination)","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"Not available","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}